Antibiotic price drop could stop millions from developing tuberculosis

Share this post

New agreement secures 66% reduction in cost of rifapentine, which prevents ‘latent’ TB from becoming active

The price of a drug crucial to prevent tuberculosis is to be slashed by two-thirds in a deal that could stop millions from developing the disease.

TB is the leading cause of death from infectious disease worldwide, killing 1.5 million people a year, according to the latest World Health Organization (WHO) global TB report.

Continue reading…

This post was syndicated from Health | The Guardian. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply